These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 33100710)
1. Effectiveness and Cost-Effectiveness of Prophylactic Voriconazole and Fluconazole Regarding Prevention of Post-hematopoietic Stem Cell Transplantation Invasive Fungal Infection and Its Related Death: A Single Center Experience. El-Ghammaz AMS; El-Zimaity M; Elafifi AM; Abdelwahed E; Moussa MM; Aboelmagd YA; Kotob MG; Fares HM Indian J Hematol Blood Transfus; 2020 Oct; 36(4):680-689. PubMed ID: 33100710 [TBL] [Abstract][Full Text] [Related]
2. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. Mauskopf J; Chirila C; Graham J; Gersten ID; Leather H; Maziarz RT; Baden LR; Bolaños-Meade J; Brown JM; Walsh TJ; Horowitz MH; Kurtzberg J; Marr KA; Wingard JR Am J Health Syst Pharm; 2013 Sep; 70(17):1518-27. PubMed ID: 23943184 [TBL] [Abstract][Full Text] [Related]
3. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience. Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of voriconazole, fluconazole, and amphotericin B for invasive fungal infections following allogeneic hematopoietic stem cell transplantation in Mexico. Morfín-Otero R; Alvarado-Ibarra M; Rodriguez-Noriega E; Resendiz-Sanchez J; Patel DA; Stephens JM; Di Fusco M; Mendoza CF; Charbonneau C Clinicoecon Outcomes Res; 2018; 10():511-520. PubMed ID: 30233223 [TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Wingard JR; Carter SL; Walsh TJ; Kurtzberg J; Small TN; Baden LR; Gersten ID; Mendizabal AM; Leather HL; Confer DL; Maziarz RT; Stadtmauer EA; Bolaños-Meade J; Brown J; Dipersio JF; Boeckh M; Marr KA; Blood; 2010 Dec; 116(24):5111-8. PubMed ID: 20826719 [TBL] [Abstract][Full Text] [Related]
6. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of antifungal prophylaxis, preemptive therapy, or empiric treatment following allogeneic hematopoietic stem cell transplant. Walker BS; Schmidt RL; Tantravahi S; Kim K; Hanson KE Transpl Infect Dis; 2019 Oct; 21(5):e13148. PubMed ID: 31325373 [TBL] [Abstract][Full Text] [Related]
13. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012 [TBL] [Abstract][Full Text] [Related]
14. Low-dose fluconazole as a useful and safe prophylactic option in patients receiving allogeneic hematopoietic stem cell transplantation. Hirade K; Kusumoto S; Hashimoto H; Shiraga K; Hagiwara S; Oiwa K; Suzuki T; Kinoshita S; Ri M; Komatsu H; Iida S Cancer Med; 2024 Feb; 13(3):e6815. PubMed ID: 38213090 [TBL] [Abstract][Full Text] [Related]
15. Invasive Fungal Infection in Hematopoietic Stem Cell Transplant Recipient from an Indian Oncology Setting. Ghafur A; Das B; Raja T; Easow J; Kartikeyan R; Easow BM; Ramanan SG South Asian J Cancer; 2024 Jul; 13(3):207-214. PubMed ID: 39410986 [TBL] [Abstract][Full Text] [Related]
16. An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol. Kunitomi A; Hasegawa Y; Hashimoto H; Saito AM; Iida H Nagoya J Med Sci; 2018 Nov; 80(4):591-595. PubMed ID: 30587873 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Sohn HS; Lee TJ; Kim J; Kim D Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111 [TBL] [Abstract][Full Text] [Related]
18. The Use of Voriconazole as Primary Prophylaxis for Invasive Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation: A Single Center's Experience. Atoui A; Omeirat N; Fakhreddine O; El Alam R; Kanafani Z; Abou Dalle I; Bazarbachi A; El-Cheikh J; Kanj SS J Fungi (Basel); 2021 Oct; 7(11):. PubMed ID: 34829213 [TBL] [Abstract][Full Text] [Related]
19. Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants. Grau S; Solano C; García-Vidal C; Jarque I; Barrueta JA; Peral C; Rodríguez I; Rubio-Rodríguez D; Rubio-Terrés C J Health Econ Outcomes Res; 2016; 3(2):153-161. PubMed ID: 35619591 [No Abstract] [Full Text] [Related]
20. Risks and outcomes of invasive fungal infections in pediatric allogeneic hematopoietic stem cell transplant recipients receiving fluconazole prophylaxis: a multicenter cohort study by the Turkish Pediatric Bone Marrow Transplantation Study Group. Hazar V; Karasu GT; Uygun V; Öztürk G; Kiliç SÇ; Küpesiz A; Daloglu H; Aksoylar S; Atay D; Ince EÜ; Karakükçü M; Özbek N; Tayfun F; Kansoy S; Özyürek E; Akçay A; Gürsel O; Haskologlu S; Kaya Z; Yilmaz S; Tanyeli A; Yesilipek A Med Mycol; 2019 Feb; 57(2):161-170. PubMed ID: 29608706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]